Takashi Fukuda
Corporate Officer/Principal at SANKYO CO., LTD.
Takashi Fukuda active positions
| Companies | Position | Start | End |
|---|---|---|---|
| SANKYO CO., LTD. | Corporate Officer/Principal | 2010-10-28 | - |
ARK Resource Co. Ltd.
 ARK Resource Co. Ltd. BiotechnologyHealth Technology ARK Resource Co. Ltd. is a Japanese company that specializes in the manufacturing of monoclonal and polyclonal antibodies, fertilized eggs in mouse/rats, and culture used for reproductive engineering. ARK Resource Co. was founded in 1966 and is based in Kumamoto, Japan, with headquarters located at 383-2 Nakahara-cho, Nishi-ku, Kumamoto-shi, Kumamoto. The company offers a wide range of services from units to g units, including the supply of mouse monoclonal antibodies by ascelonus method and culture method. The company also provides a quick diagnostic genetic modified animal breeding colony by the service introduction pcr method, performing homo / hetero / wild type screening (geno typing). The company can identify specific disease bacteria in biological samples and culture cells. | Director/Board Member | - | - |
| Corporate Officer/Principal | - | - |
Career history of Takashi Fukuda
Statistics
International
| Japan | 3 |
Operational
| Corporate Officer/Principal | 2 |
| Director/Board Member | 1 |
Sectoral
| Producer Manufacturing | 2 |
| Health Technology | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 1 |
|---|---|
| SANKYO CO., LTD. | Producer Manufacturing |
| Private companies | 1 |
|---|---|
ARK Resource Co. Ltd.
ARK Resource Co. Ltd. BiotechnologyHealth Technology ARK Resource Co. Ltd. is a Japanese company that specializes in the manufacturing of monoclonal and polyclonal antibodies, fertilized eggs in mouse/rats, and culture used for reproductive engineering. ARK Resource Co. was founded in 1966 and is based in Kumamoto, Japan, with headquarters located at 383-2 Nakahara-cho, Nishi-ku, Kumamoto-shi, Kumamoto. The company offers a wide range of services from units to g units, including the supply of mouse monoclonal antibodies by ascelonus method and culture method. The company also provides a quick diagnostic genetic modified animal breeding colony by the service introduction pcr method, performing homo / hetero / wild type screening (geno typing). The company can identify specific disease bacteria in biological samples and culture cells. | Health Technology |
- Stock Market
- Insiders
- Takashi Fukuda
- Experience